ECHA Proposes to Include 18 New Substances in REACH
On September 5, 2018, the European Chemicals Agency ("ECHA") launched a public consultation to include 18 new substances in Annex XIV REACH. REACH, the acronym for the Registration, Evaluation, Authorisation and Restriction of Chemicals, is an EU regulation that addresses the production and use of chemical substances, as well as their potential impacts on human health and the environment. ECHA's consultation is open for comments until December 5, 2018.
The substances under consideration for authorization include the following:
Simultaneously, the European Commission will be investigating the socioeconomic impact of inclusion of the substances into Annex XIV. After the public consultation and the Member State Committee's opinion, the Commission will make a final decision on insertion into Annex XIV.
By way of background, once a substance is listed in Annex XIV, it may no longer be used in the European Union unless a company-specific "Authorization" has been granted, which is a lengthy and expensive procedure (Title VII of REACH) involving ECHA, the Commission, and EU Member States. Moreover, each Authorization is subject to regular review, repeating the lengthy and expensive procedure. Either manufacturers or importers of the substance or the actual users can apply for Authorization.
Lawyer Contacts
For more information, please contact your principal Jones Day representative or the lawyers below. General email messages may be sent using our "Contact Us" form, which can be found at www.jonesday.com/contactus/.
Ursula Schliessner
Brussels
+32.2.645.14.60
uschliessner@jonesday.com
Preslava Dilkova
Brussels
+32.2.645.14.53
pdilkova@jonesday.com
Jones Day publications should not be construed as legal advice on any specific facts or circumstances. The contents are intended for general information purposes only and may not be quoted or referred to in any other publication or proceeding without the prior written consent of the Firm, to be given or withheld at our discretion. To request reprint permission for any of our publications, please use our "Contact Us" form, which can be found on our website at www.jonesday.com. The mailing of this publication is not intended to create, and receipt of it does not constitute, an attorney-client relationship. The views set forth herein are the personal views of the authors and do not necessarily reflect those of the Firm.
